TLP
RVMD icon

Tri Locum Partners’s Revolution Medicines RVMD Stock Holding History

Tri Locum Partners’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.4M Buy
+151,822
New +$22.2M 3.5% 11
2022
Q3 		– Sell
-148,453
Closed -$2.89M – 58
2022
Q2 		$2.89M Sell
148,453
-22,002
-13% -$428K 1.18% 24
2022
Q1 		$4.35M Buy
+170,455
New +$3.71M 1.7% 25

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Tri Locum Partners's RVMD Position: Q2 2026 in Review

Tri Locum Partners opened a new position in Revolution Medicines (RVMD) in Q2 2026: 151,822 shares worth $28.4M. The stake represents 3.5% of the portfolio and ranks #11 among its holdings. This is a return to the name: Tri Locum Partners previously reported a position in RVMD as recently as Q2 2022.

Tri Locum Partners first reported a position in RVMD in Q1 2022 and has held it in 3 quarters since. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Tri Locum Partners held 151,822 shares of Revolution Medicines worth $28.4M as of Q2 2026.
  • Revolution Medicines was a new Tri Locum Partners position in Q2 2026.
  • Revolution Medicines made up 3.5% of Tri Locum Partners's portfolio in Q2 2026, its #11 holding.
  • Tri Locum Partners first reported a position in Revolution Medicines in Q1 2022 and has held it in 3 quarters since.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Tri Locum Partners's 13F filing for Q2 2026, filed 14 Aug 2026.